ClinicalTrials.gg
CompletedNCT01627613Updated Nov 18, 2019

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

A Phase 2 interventional study of AP301 and Saline solution in Acute Lung Injury, sponsored by Apeptico Forschung und Entwicklung GmbH. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Apeptico Forschung und Entwicklung GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Acute Lung Injury with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Acute Lung Injury · Austria.

Started
2012
the only one that year
Phase 2
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Apeptico Forschung und Entwicklung GmbH

Among the 10 studies in Acute Lung Injury with a site in Austria, this one is the only one that started in 2012, is the only one in phase 2, and was the 3rd registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

3 of the 10 studies in Acute Lung Injury with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Acute Lung Injury with a site in Austria, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of orally inhaled AP301 on alveolar liquid clearance in ALI (acute lung injury) patients with the purpose to assess the treatment associated changes of extravascular lung water (EVLW) within 7 days of treatment.

03

Conditions studied

  • Acute Lung Injury

Browse trials for

Keywords

  • Peptide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18
  • intubated and mechanically ventilated male and female patients of the Intensive Care Units of the Department of Anesthesia, General Intensive Care and Pain Control
  • meets the criteria of ALI (as defined by the American-European Consensus Conference on ALI/ ARDS):
  • Onset of ALI within 48 hours
  • Bilateral infiltrates seen on frontal chest radiograph
  • PCWP ≤ 18 mm Hg or no clinical evidence of left atrial hypertension
  • paO2/ FiO2 ratio ≤ 300 mm Hg
  • EVLW in PiCCO® at screening ≥ 8 ml/PBW
  • Meeting criteria for extensive hemodynamic monitoring according to investigators discretion
  • ICU Patients being mechanically ventilated and are stable in this condition for at least 8 hours
  • Negative pregnancy test and adequate in female patients of
  • :
  • For patients that are temporarily unable to consent (e.g. comatose patients) a subsequent informed consent has to be provided.

Exclusion criteria

Exclusion Criteria:

  • History of allergies or idiosyncrasies to AP301 or any other inactive ingredient(s) of the product
  • Brainstem death at screening
  • Current evidence of septic shock as defined by the Surviving Sepsis Campaign (Presence of acute organ dysfunction secondary to infection plus hypotension with systolic blood pressure \< 90 mm Hg or mean arterial pressure (MAP) \< 70 mm Hg for not less than one hour which cannot be reversed with fluid resuscitation)
  • \<0.3 x 109 L
  • Patients under : high dose (> 80 mg Prednisolone /d; > 300 mg hydrocortisone / d), cancer treatment (chemotherapy or biological) or therapy with other immunosuppressive agents for organ transplantation within 2 weeks
  • \< 18.5 or > 35
  • Cardiogenic pulmonary edema diagnosed by echocardiography or pulmonary artery catheter
  • Pregnancy / lactation or intention to fall pregnant during the time course of the study
  • Women of as well as men of procreative capacity who are not using adequate
  • Participation in other interventional drug trials
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    AP301

    Treatment group

    Drug: AP301

  • Placebo comparator
    saline solution

    Placebo group

    Drug: Saline solution

Interventions

  • DrugAP301

    AP301 25 mg powder for reconstitution for solution for inhalation Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days.

  • DrugSaline solution

    Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.

06

What researchers measure

Primary outcomes

  1. change in extravascular lung water within 7 days of treatment

    EVWL (measured with PiCCO® technique) until day 7 of treatment (AUC)

    Time frame: change from baseline - day 7

Secondary outcomes

  1. Oxygenation index

    Oxygenation index (PaO2 / FiO2 ratio) until day 7 of treatment

    Time frame: baseline - day 7

  2. ventilator plateau pressure

    Ventilator plateau pressure until day 7 of treatment

    Time frame: baseline - day 7

  3. Murray Lung Injury Score

    Time frame: baseline - day 7

  4. Ventilation parameters / lung function

    Time frame: baseline - day 7

  5. Presence/absence/severity and duration of adverse effects - number and severity of adverse events (AEs), serious adverse events (SAEs) and suspected unexpected serious adverse events (SUSARs))

    Time frame: baseline - day 7

07

Study locations

1 site
  • Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna
    Vienna, 1090, Austria
08

References and documents

Publications

  • Krenn K, Lucas R, Croize A, Boehme S, Klein KU, Hermann R, Markstaller K, Ullrich R. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Crit Care. 2017 Jul 27;21(1):194. doi: 10.1186/s13054-017-1795-x. PubMed 28750677 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2012
First posted
Jun 26, 2012
Start
Jul 2012
Primary completionActual
May 2014
CompletionActual
Aug 2014
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01627613
Lead sponsor
Apeptico Forschung und Entwicklung GmbH
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
Jul 2012
Primary completion
May 2014
Completion
Aug 2014
Last update
Nov 18, 2019

Study contacts

Roman Ullrich, Prof.
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP301 peptide

Start the discussion